MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University...

26
MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego

Transcript of MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University...

Page 1: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

MANAGEMENT OF INTRACEREBRAL HEMORRHAGENavaz Karanjia, MD

Director of Neurocritical Care

University of California – San Diego

Page 2: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Intracerebral Hemorrhage

Page 3: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Intracerebral Hemorrhage

Page 4: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Intracerebral Hemorrhage

Page 5: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Neurocritical Care Management of Intracerebral Hemorrhage Epidemiology

10-15% of all strokes, 50-70,000 cases/yr in US Presentation

Headache, neurologic deficit Outcomes

40% 30-day mortality Reduced by 17% by an NCCU/neurointensivist

20% independent at 6 monthsImproves by 21% by an NCCU/neurointensivist

Mirski M, Chang CW, and Cowan R. J Nsurg Anesth 2001; 13(2): 83-92.

Lancet Neurol. 2010 Feb;9(2):167-76. doi: 10.1016/S1474-4422(09)70340-0

Page 6: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Intracerebral Hemorrhage

Causes of ICH

Page 7: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Intracerebral Hemorrhage

Common locations for hypertensive ICH

Thalamus Cerebellum Pons Basal Ganglia

Page 8: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Intracerebral Hemorrhage

Clinical course and complications

Tissue dissection, displacement, increased ICP (immediate)

Hematoma expansion (immediate ->36h)HydrocephalusNeurohemoinflammation/Cerebral edema (day 2-5)SeizuresCentral fever

Page 9: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Intracerebral Hemorrhage

Hematoma expansion72% have some hematoma expansion over 24h

38% have clinically significant expansion within 24h

Within 1 hr in 26% of casesWorsens outcome

Page 10: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.
Page 11: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Neurocritical Care Management of Intracerebral Hemorrhage Preventing hematoma expansion (INTERACT,

ATACH) IMMEDIATE BP control reduces expansion 30%

Target SBP 140-150 with nicardipine drip or labetalol/hydralazine IVP WITHIN 10 MINUTES

IMMEDIATE coagulopathy reversal FFP, PCC (KCentra) within 30 minRecheck coags 15 min post PCCPlatelets if <100,000 or TEG abnlNOT factor VII (FAST trial)Time to reversal is being tracked

Page 12: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

PCC (Profilnine) Pathway

History of thrombotic event in past 6 wks? (DVT, PE, trauma, ischemic stroke, ACS, mesenteric ischemia, etc)Major surgery within 6 weeks? Heparin induced thrombocytopenia (HIT)?

UCSD Reversal Protocol for Spontaneous Intracerebral Hemorrhage with INR > 1.4

• INR 2-4: infuse 25 units/kg body weight* Profilnine over 5 min, not to exceed 2ml/min

• INR >4: infuse 40 units/kg body weight* Profilnine over 10 minutes, not to exceed 2ml/min

• Repeat INR 15 minutes after infusion complete. If INR not at target, repeat q15 min x2 until INR at target. Once INR ≤1.4, repeat INR every 6 hrs for 24 hrs. If INR > 145, give another 10mg vitamin K IV/PO and consider 2 more units FFP.

• If INR does not reach target in 45 minutes, consider Factor 7, 20-40 mcg/kg (1-3mg) IV x 1

At 24 hrs, repeat dose of Vitamin K 10 mg IV/PO * in obese patients, base dose on a maximum weight of ideal body weight + 20% ***

Check the following labs at 1 hr and q6 hrs after completion of PCC infusion: PT/INR, EKG and Cardiac enzymes, Fibrinogen

INR > 2.0

• STAT Labs: PT/INR, PTT, fibrinogen, platelets, CBC, Type and Screen, troponin• If crash craniotomy considered, type and cross 2U PRBC

• Give vitamin K 10mg IV stat; if IV not available, give 10mg PO• Transfuse 2U FFP stat over 30 min. If type&screen will take >30 min and INR>2, transfuse 2U

uncrossmatched FFP. If pt cannot tolerate FFP due to volume overload, use PCC+Factor 7 20-40mcg/kg (1-3 mg)

FFP Pathway

• Immediately give 2 more units FFP • Repeat coags upon completion of infusion• If INR still >1.4, 2 more units FFP • If still > 1.4, consider PCC and consult hematology• Once INR ≤1.4, repeat INR q4-6 hrs for 24-48 hrs

Can patient tolerate more FFP (volume status)?YES

NO YES

INR 1.4 – 2.0

NO

Page 13: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Stat labs at 15 min and q6 hours after completion of PCC infusion: PT/INR, TT, EKG, cardiac enzymes, fibrinogen, anti-Xa level. If TT or PT/INR is still prolonged AND patient still bleeding/extreme risk of hematoma expansion, consider repeating Profilnine dose or giving Factor 7, 20-40mcg/kg (1-3mg) IV x1

UCSD Reversal Protocol for Spontaneous Intracerebral Hemorrhage on Dabigatran, Rivaraoxaban, or Apixaban

• STAT labs: PT/INR, fibrinogen, platelets, CBC, PTT, TT, anti-Xa level , Type & Screen• If crash craniotomy considered, type and cross 2U PRBC

IF ON DABIGATRAN (direct thrombin inhibitor )

and TT prolongedIF ON RIVAROXABAN or APIXABAN (factor Xa inhibitor)

and PT/INR is prolonged or anti-Xa level elevated

IF ingestion within 2 hrs, give one dose activated charcoal orally

• infuse 25 units/kg (+/- 10%) body weight* PCC (Profilnine) over 5 minutes, not to exceed 2ml/min• Transfuse 2 units FFP STAT. If type and screen will take >30 min, transfuse 2 units uncrossmatched FFP.

Emergent dialysis may be considered in certain circumstances (renal failure, overdose); ~ 65% removed by hemodialysis

Dabigatran t ½ = 14 hrs (up to 34 hrs in severe renal impairment)

Rivaroxaban and Apixaban are NOT dialyzable

Rivaroxaban t 1/2 = 9 hrs (longer in renal impairment)Apixaban t ½ = 12 hrs (longer in renal impairment)

* in obese patients, use maximum weight of ideal body weight + 20%

Page 14: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Neurocritical Care Management of Intracerebral Hemorrhage Acute obstructive hydrocephalus

occurs in 50-70% of IVH patients treat with emergent EVD Intraventricular tPA for IVH clears IVH faster (11.4-

>2.6 days), likely reduces hydrocephalus/need for VP shunt, ? mortality/outcomes (CLEAR-IVH)

Huttner HB, Tognoni E et al. Eur J Neurol. 2008;15(4):342.

Page 15: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Intracerebral Hemorrhage

Neurohemoinflammation/cerebral edemaPeaks days 2-5Exacerbated by fever and seizureMedical cerebral edema treatment ((hypertonic saline, normothermia, seizure control, ventilation control)

Surgical/endoscopic clot removal

Page 16: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Neurocritical Care Management of Intracerebral HemorrhageSurgical clot removal (MISTIE II, STICH II trials)Endoscopic for deep clots

Improves good outcome 20% 34%

Open for all superficial clotsReduces mortality (STICH II)

Page 17: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Neurocritical Care Management of Intracerebral Hemorrhage

MISTIE II

Hanley, D et al. Mistie II Trial Results: 365 day outcome and cost-benefit. ISC 2013 Late Breaking Newshttp://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_449055.pdf

Page 18: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Seizure control33% of altered ICH patients have seizures, most are nonconvulsiveSeizures worsen ICP, midline shiftAll altered ICH pts should receive

continuous EEG monitoring (Class I, LOE B )

Claassen et al. Anesthesia Analg. Vol. 109, No. 2, August 2009

2012 Neurocritical Care Society Guidelines:

Indications for Continuous EEG

Monitoring

Neurocritical Care Management of Intracerebral Hemorrhage

Page 19: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Neurocritical Care Management of Intracerebral Hemorrhage

Vespa et al Neurology 2003

Seizures after ICH leads to worsening midline shift

Page 20: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Neurocritical Care Management of Intracerebral Hemorrhage

Vespa et al Neurology 2003

Seizures after ICH leads to worsening midline shift

Page 21: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Neurocritical Care Management of Intracerebral Hemorrhage

Vespa et al Neurology 2003

Seizures after ICH leads to worsening midline shift

Page 22: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Intracerebral Hemorrhage

Antiepileptics are indicated ONLY if the patient demonstrates evidence of seizure clinically or on EEG (prophylactic AED’s worsen outcome, OR mRS>3 = 9.8).

Class I, LOE B

AED PROPHYLAXIS?

Naidech et al, Stroke 2009

Page 23: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Intracerebral Hemorrhage

Central feverOccurs in 70% of patientsIncreases cerebral metabolic rate, ICP, and midline shiftNormothermia should be maintained and fever treated aggressively, using antipyretics and intravascular/surface cooling devices if needed (Class I, LOE B recommendation)

Page 24: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Neurocritical Care Management of Intracerebral Hemorrhage

Normothermia, glycemic control, dysphagia screening

Lancet 2011: For all hemorrhagic and ischemic stroke patients, implementation of an RN protocol to treat any temp≥37.5, glycemic control, dysphagia screening decreases death/dependence 58% -> 42%, NNT 6.4

Page 25: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Intracerebral Hemorrhage

Page 26: MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University of California – San Diego.

Neurocritical Care Management of Intracerebral Hemorrhage